FINWIRES · TerminalLIVE
FINWIRES

ASX:OCC

10 stories mentioning ASX:OCCUpdated 20d ago

Every FINWIRES story that references ASX:OCC, newest first.

Asia

Orthocell June Quarter Highlights Strong Revenue Growth, Euroz Hartleys Says

Orthocell (ASX:OCC) delivered strong fiscal year 2026 revenue growth while continuing to expand the US commercial rollout of Remplir, with improving hospital access and surgeon adoption supporting its long-term growth outlook, Euroz Hartleys said in a Tuesday note.The company reported June-quarter revenue of AU$3.8 million, up 20% from the previous quarter, bringing fiscal year 2026 revenue to AU$13.2 million, a 44% increase from the prior year and broadly in line with the research firm's expectations.Euroz Hartleys said its investment thesis continues to depend on the US commercial rollout of Remplir, with quarterly US sales increasing 10% as 119 units were sold during the period.The research firm noted that the company strengthened its US rollout, expanding to 18 distributors across 20-plus states while Value Analysis Committee approvals rose 38% to 44, giving Remplir access to 151 hospitals, with 64 applications still under review.The research firm highlighted stronger Remplir adoption, with hospital uptake rising 27% quarter-on-quarter to 70 and surgeon adoption increasing 55% to 76, while targeting 100 to 150 hospitals and 150 to 200 surgeons across more than 30 US states in fiscal 2027.It added that international Remplir revenue exceeded 9% of quarterly sales, supported by new distributors in Canada and Thailand, with UK and European approvals expected by year's end, ahead of launches in the first half of 2027.Euroz Hartleys maintained its speculative buy recommendation on Orthocell while raising its price target to AU$1.10 per share from AU$1.09.

ASX:OCC
Asia

Orthocell Says June Quarter Revenue Rises 36% Year-over-Year to New Record

Orthocell (ASX:OCC) said its revenue came in at AU$3.8 million for the June quarter, up 36% year-over-year from AU$2.8 million in the prior-year quarter, according to a Monday Australian bourse filing.Cash receipts from customers totalled AU$2.5 million for the quarter, compared to AU$1.6 million in the prior quarterIts revenue for fiscal year 2026 came in at AU$13.2 million, up 44%.The firm attributed the rise in revenue to continued adoption of Remplir in Australia and accelerating commercial adoption in the US. Total international revenue from Remplir sales comprises 9% of total quarterly revenue.

ASX:OCC
Asia

Orthocell Appoints MediTime as Exclusive Thai Distributor for Remplir Nerve Repair Product

Orthocell (ASX:OCC) appointed MediTime as its exclusive in-country distributor for its nerve repair product Remplir in Thailand, according to a Friday Australian bourse filing.The company said MediTime's clinical education platform, key opinion leader (KOL) relationships, hospital access, and logistics network are expected to accelerate the engagement and adoption of Remplir throughout Thailand.The company added that the appointment further strengthens Orthocell's expanding Asian distribution network, with product sales underway in Australia, Singapore, and Hong Kong, while the company continues to focus resources on the US market, where recent approvals have expanded access to around 336 hospitals, including 221 US military medical centers.

ASX:OCC
Asia

Orthocell Ships Remplir Nerve Repair Product for Ukraine Philanthropy Effort; Shares Fall Nearly 4%

Orthocell (ASX:OCC) said Monday it has shipped its Remplir nerve repair products to Ukraine after a group of Australian corporate donors agreed to purchase 100 units of the device to send to the Eastern European country.The company said in a statement that the Ukraine Crisis Appeal pledged AU$10,000 to support this effort.The company's shares fell nearly 4% in recent trading on Monday.

ASX:OCC
Asia

Orthocell Completes First Commercial Sales of Remplir Nerve Repair Device in Canada

Orthocell (ASX:OCC) has completed first commercial sales of its Remplir nerve repair device in Canada, a milestone in the global rollout of its peripheral nerve reconstruction product, according to a Thursday Australian bourse filing.The company said Remplir is now approved for sale and generating revenue in Australia, New Zealand, the US, Singapore, Hong Kong, and Canada, with expansion planned into the EU and UK markets following expected approval in the second half of calendar 2026.Orthocell held more than AU$48 million in cash as at March 31, with no debt, it added.

ASX:OCC
Asia

Orthocell Says Post-Market Follow-Up Study Shows Overall Treatment Success Rate of Nearly 90% for Nerve Repair Product; Shares Jump 4%

Orthocell (ASX:OCC) said results from an ongoing multi-center post-market clinical follow-up study for its nerve repair product, Remplir, showed an overall treatment success rate of nearly 90%, based on performance data from 66 patients, according to a Tuesday Australian bourse filing.The company said over 90% of motor nerve repairs resulted in functional muscle recovery, while more than 89% of nerve decompression procedures resulted in complete relief or significant improvement of symptoms.The patients were aged 14 to 82 years, and the majority of the procedures were performed in the upper limb. No post-treatment complications or adverse effects were reported.Orthocell's shares jump nearly 4% in recent trading on Tuesday.

ASX:OCC
Asia

Orthocell's Fiscal Year 2026 Revenue Estimate Cut to AU$13.4 Million, Euroz Hartleys Says

Orthocell's (ASX:OCC) fiscal year 2026 revenue is now estimated to reach AU$13.4 million, revised down from AU$14.4 million, Euroz Hartleys said in a note on Tuesday.Orthocell said it achieved a revenue of AU$3.2 million in the March quarter, in line with the prior quarter and primarily driven by sales of its nerve repair product, Remplir. Its management attributed the flat quarterly revenue growth to seasonality.Euroz Hartleys says that Orthocell has delivered around 8.5% compound quarterly revenue growth over the past 15 quarters.The investment firm maintained its speculative buy recommendation on Orthocell and lowered its price target to AU$1.09 per share from AU$1.19 per share.

ASX:OCC
Asia

Orthocell Says March Quarter Revenue in Line With Prior Quarter; Shares Down 5%

Orthocell (ASX:OCC) said it achieved a revenue of AU$3.2 million in the March quarter, in line with the prior quarter and primarily driven by sales of its nerve repair product, Remplir, according to a Monday Australian bourse filing.The company expects a material uplift in US revenue in the upcoming quarters after the establishment of a commercial distribution platform in the country, with its network expanded to cover over 16 states and around 40% of the population.Regulatory approval for the commercial distribution of Remplir in the US and UK is anticipated in the second half of 2026.Orthocell's shares fell past 5% in recent trading on Monday.

ASX:OCC
Asia

Orthocell Says First Surgical Case Using Nerve Repair Product in US Department of Defense Hospital Network Completed

Orthocell (ASX:OCC) said that a surgery at a military base hospital in Ohio within the US Department of Defense/Veterans Affairs hospital network was the first surgical case using its nerve repair product, Remplir, according to a Friday Australian bourse filing.The company said that this represented an important step in its US commercialization strategy.

ASX:OCC
Asia

Orthocell Wins Approval for Nerve Repair Device Across US Military, VA Hospital Networks

Orthocell (ASX:OCC) said it has secured approval for its Remplir nerve repair device to be used across the US Department of Defense and Veterans Affairs hospital networks, according to a Wednesday Australian bourse filing.The company said it will use its existing US distributor network to target military and VA surgeons operating within these hospital systems, which currently covers 17 states.The approval comes as Orthocell said it is seeing growing evidence of increasing commercialization and revenue momentum in the US market.

ASX:OCC

Track with the FINWIRES app suite

FolioX
FolioX
Track ASX:OCC in your portfolio
WheelAI
WheelAI
Analyze ASX:OCC options with the wheel strategy
StockInsider
StockInsider
See market sentiment on ASX:OCC